Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ariane Laparra

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Current Opinion in Oncology|January 27, 2025
Immuno-oncology in the daily practiceAriane Laparra
Soins; La Revue De Reference Infirmiere|September 7, 2025
[The toxicity pathway, an innovation for managing the toxicity of cancer treatments]Delphine Mathivon, Ariane Laparra, Florian Scotté, et al.
La Revue Du Praticien|June 23, 2021
[Management of adverse events associated with cancer immunotherapy]Ariane Laparra, Stéphane Champiat, Jean-Marie Michot, et al.
Bulletin Du Cancer|May 19, 2023
[Electrolyte disorders in oncological patients]Arnaud Saillant, Mélanie Try, Ariane Laparra, et al.
Bulletin Du Cancer|December 6, 2024
[Acute kidney injury in cancer patients receiving immune checkpoint inhibitor therapy-shared guidelines of FITC/SFNDT]Victor Gueutin, Stéphane Dalle, Corinne Isnard-Bagnis, et al.
Journal for Immunotherapy of Cancer|September 24, 2025
Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockadeRomain Guitton, Ariane Laparra, Noemie Chanson, et al.
Respiratory Medicine and Research|November 12, 2022
Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitorsMarion Camard, Benjamin Besse, Pierre-Louis Cariou, et al.
JMIR Research Protocols|August 26, 2024
Evaluating the Implementation of Integrated Proactive Supportive Care Pathways in Oncology: Master Protocol for a Cohort StudyMaria Alice Franzoi, Arnaud Pages, Loula Papageorgiou, et al.
JAMA Network Open|September 10, 2025
Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung CancerAdrien Rousseau, Noémie Simon-Tillaux, Stefan Michiels, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2021
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registryValentine Ruste, Vincent Goldschmidt, Ariane Laparra, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Current Opinion in Oncology|January 27, 2025
Immuno-oncology in the daily practiceAriane Laparra
Soins; La Revue De Reference Infirmiere|September 7, 2025
[The toxicity pathway, an innovation for managing the toxicity of cancer treatments]Delphine Mathivon, Ariane Laparra, Florian Scotté, et al.
La Revue Du Praticien|June 23, 2021
[Management of adverse events associated with cancer immunotherapy]Ariane Laparra, Stéphane Champiat, Jean-Marie Michot, et al.
Bulletin Du Cancer|May 19, 2023
[Electrolyte disorders in oncological patients]Arnaud Saillant, Mélanie Try, Ariane Laparra, et al.
Bulletin Du Cancer|December 6, 2024
[Acute kidney injury in cancer patients receiving immune checkpoint inhibitor therapy-shared guidelines of FITC/SFNDT]Victor Gueutin, Stéphane Dalle, Corinne Isnard-Bagnis, et al.
Journal for Immunotherapy of Cancer|September 24, 2025
Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockadeRomain Guitton, Ariane Laparra, Noemie Chanson, et al.
Respiratory Medicine and Research|November 12, 2022
Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitorsMarion Camard, Benjamin Besse, Pierre-Louis Cariou, et al.
JMIR Research Protocols|August 26, 2024
Evaluating the Implementation of Integrated Proactive Supportive Care Pathways in Oncology: Master Protocol for a Cohort StudyMaria Alice Franzoi, Arnaud Pages, Loula Papageorgiou, et al.
JAMA Network Open|September 10, 2025
Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung CancerAdrien Rousseau, Noémie Simon-Tillaux, Stefan Michiels, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2021
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registryValentine Ruste, Vincent Goldschmidt, Ariane Laparra, et al.
Pageof 3